- Home
- RVT vs TSHA Comparison
RVT vs TSHA Comparison
Compare RVT & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVT | TSHA |
|---|---|---|
| Founded | 1986 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RVT | TSHA |
|---|---|---|
| Price | $18.04 | $6.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.63 |
| AVG Volume (30 Days) | 360.3K | ★ 2.3M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 7.32% | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ 2.95 | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,152.42 |
| P/E Ratio | $6.08 | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $14.78 | $2.25 |
| 52 Week High | $18.88 | $7.30 |
Technical Indicators
Market Signals| Indicator | RVT | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 65.46 |
| Support Level | $18.06 | $4.39 |
| Resistance Level | $18.78 | $6.76 |
| Average True Range (ATR) | 0.39 | 0.38 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 66.67 | 95.85 |
Price Performance
Historical ComparisonAbout RVT Royce Value Trust Inc.
Royce Small-Cap Trust Inc is a diversified closed-end investment company that invests in equity securities of small-cap companies. The company portfolio includes sectors such as Industrials, Financials, Information Technology, Health Care, and Consumer Discretionary.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.